文献速递急性肾损伤慢性肾脏病

达格列净与COVID-19感染住院患者肾脏结局:DARE-19随机对照试验分析

Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2022-04-28

DARE-19试验二次分析纳入1250例COVID-19住院患者(231例基线eGFR<60 ml/min per 1.73 m2),比较达格列净与安慰剂对肾脏结局的影响。达格列净对主要预防结局(HR 0.80,95%CI 0.58-1.10)、主要恢复结局(win ratio 1.09,95%CI 0.97-1.22)及复合肾脏结局(HR 0.74,95%CI 0.50-1.07)的效应在eGFR亚组间一致,耐受性良好,未增加AKI风险。

要点

  • 达格列净对复合肾脏结局的效应在eGFR<60与≥60 ml/min per 1.73 m2亚组间一致(交互P=0.44)。
  • 达格列净组复合肾脏结局HR 0.74(95%CI 0.50-1.07),未达统计学显著。
  • 达格列净在eGFR<60和≥60 ml/min per 1.73 m2患者中均耐受良好,未增加AKI风险。

核心结论

  • 在COVID-19住院患者中,达格列净对主要和次要结局的效应在eGFR低于/高于60 ml/min per 1.73 m2者中一致。
  • 达格列净耐受良好,在eGFR低于或高于60 ml/min per 1.73 m2的患者中未增加AKI风险。

研究设计与样本

  • DARE-19试验的二次分析,随机对照试验,纳入1250例COVID-19住院且伴心血管代谢危险因素的患者,其中231例(18%)基线eGFR<60 ml/min per 1.73 m2。
  • 患者随机接受达格列净或安慰剂,按基线eGFR<60和≥60 ml/min per 1.73 m2评估结局。

主要发现

  • 达格列净 vs 安慰剂的主要预防结局HR 0.80(95%CI 0.58-1.10),主要恢复结局win ratio 1.09(95%CI 0.97-1.22),复合肾脏结局HR 0.74(95%CI 0.50-1.07)。
  • 上述结局在eGFR亚组间一致,交互P值分别为0.98、0.67和0.44。
  • AKI风险在eGFR<60 ml/min per 1.73 m2组HR 0.71(95%CI 0.29-1.77),在eGFR≥60 ml/min per 1.73 m2组HR 0.69(95%CI 0.37-1.29)。
  • 达格列净在eGFR<60和≥60 ml/min per 1.73 m2患者中均耐受良好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Patients who were hospitalized with coronavirus disease 2019 (COVID-19) infection are at high risk of AKI and KRT, especially in the presence of CKD. The Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19) trial showed that in patients hospitalized with COVID-19, treatment with dapagliflozin versus placebo resulted in numerically fewer participants who experienced organ failure or death, although these differences were not statistically significant. We performed a secondary analysis of the DARE-19 trial to determine the efficacy and safety of dapagliflozin on kidney outcomes in the overall population and in prespecified subgroups of participants defined by baseline eGFR. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The DARE-19 trial randomized 1250 patients who were hospitalized (231 [18%] had eGFR <60 ml/min per 1.73 m2) with COVID-19 and cardiometabolic risk factors to dapagliflozin or placebo. Dual primary outcomes (time to new or worsened organ dysfunction or death, and a hierarchical composite end point of recovery [change in clinical status by day 30]), and the key secondary kidney outcome (composite of AKI, KRT, or death), and safety were assessed in participants with baseline eGFR <60 and ≥60 ml/min per 1.73 m2. RESULTS: The effect of dapagliflozin versus placebo on the primary prevention outcome (hazard ratio, 0.80; 95% confidence interval, 0.58 to 1.10), primary recovery outcome (win ratio, 1.09; 95% confidence interval, 0.97 to 1.22), and the composite kidney outcome (hazard ratio, 0.74; 95% confidence interval, 0.50 to 1.07) were consistent across eGFR subgroups (P for interaction: 0.98, 0.67, and 0.44, respectively). The effects of dapagliflozin on AKI were also similar in participants with eGFR <60 ml/min per 1.73 m2 (hazard ratio, 0.71; 95% confidence interval, 0.29 to 1.77) and ≥60 ml/min per 1.73 m2 (hazard ratio, 0.69; 95% confidence interval, 0.37 to 1.29). Dapagliflozin was well tolerated in participants with eGFR <60 and ≥60 ml/min per 1.73 m2. CONCLUSIONS: The effects of dapagliflozin on primary and secondary outcomes in hospitalized participants with COVID-19 were consistent in those with eGFR below/above 60 ml/min per 1.73 m2. Dapagliflozin was well tolerated and did not increase the risk of AKI in participants with eGFR below or above 60 ml/min per 1.73 m2.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Heerspink HJL, Furtado RHM, Berwanger O, et al. Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled Trial. Clin J Am Soc Nephrol. 2022. PMID: 35483733. doi:10.2215/CJN.14231021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。